Injective Protocol (INJ) has received significant institutional validation as Nasdaq approved the listing application for Canary Capital's Staked INJ ETF under the ticker INJC. This development marks a major milestone for the protocol, coming just days after the filing was submitted to the Securities and Exchange Commission.
The approved ETF structure will stake a minimum of 90% of its INJ holdings under normal circumstances, creating a substantial demand floor for the token. BitGo has been selected as the custodian for this institutional-grade fund, and shareholders will pay a 1.10% annual sponsor fee for the managed exposure.
However, public trading remains conditional upon the effectiveness of the S-1 registration statement, which is still in the pre-effective review period.
Industry analysts say this move represents a turning point for Injective's institutional adoption narrative. The 90% staking requirement directly addresses concerns about token supply inflation while providing clear upside potential for INJ holders. This approach differs from traditional ETF structures by actively managing token utility through network participation rather than passive ownership.
The news comes as Injective's ecosystem continues to show strong momentum. The protocol's native token surged 10.73% to $8.01 following the Nasdaq approval announcement, with prices holding above key moving averages across multiple timeframes. Traders attribute this rally to renewed institutional interest sparked by the ETF prospect, noting the approval signals growing regulatory comfort with blockchain-based investment products.
ETF launch timing now emerges as a critical catalyst for institutional demand. The regulatory approval process has proven more rigorous than initially expected, with the S-1 registration statement still pending effectiveness. However, industry sources suggest the application has strong support within SEC review circles, potentially clearing the path for trading as early as Q1 2027 if the registration becomes effective.
The broader market context shows crypto assets struggling to maintain recent gains, making Injective's ETF-driven momentum particularly noteworthy. Technical analysts highlight that INJ's price action demonstrates clear institutional buying pressure, with the token maintaining structural support levels that suggest further upside potential. The Nasdaq listing approval is both validation and catalyst for the protocol's long-term growth trajectory.